U.S. Markets close in 6 hrs 13 mins

Amarantus Bioscience Holdings, Inc (AMBS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.04+0.00 (+1.27%)
As of 9:30AM EDT. Market open.
People also watch
ELTPONCSIGXTMSTXNVIV
Full screen
Previous Close0.04
Open0.04
Bid0.00 x
Ask0.00 x
Day's Range0.04 - 0.04
52 Week Range0.01 - 0.09
Volume18,700
Avg. Volume126,968
Market Cap3.15M
Beta-0.40
PE Ratio (TTM)-0.01
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Researchlast year

    AMBS: Update on Diagnostics Business

    On Jan 19, Amarantus (AMBS) and Avant Diagnostics (AVDX) announced they have entered into a Letter of Intent to merge an Amarantus wholly-owned subsidiary, Amarantus Diagnostics, into Avant Diagnostics. Under the terms of the LOI, upon execution of definitive merger agreements, Avant shall issue to Amarantus 80 million shares of common stock of Avant Diagnostics, representing approximately 45% of Avant's post-merger common stock, and 10 million additional shares of common stock upon achievement of certain sales milestones.

  • Zacks Small Cap Researchlast year

    AMBS: Amarantus Updates its cGMP Manufacturing Technical Transfer

    By Grant Zeng, CFA Earlier this morning (Feb 22), Amarantus (OTCQB: AMBS), provided an update on the status of its cGMP manufacturing technical transfer for producing ESS at Lonza Walkersville, Inc., a ...

  • Zacks Small Cap Researchlast year

    AMBS: Amarantus Eltoprazine Granted Orphan Drug Designation for PD-LID

    Eltoprazine is a small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression. Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established safety profile.